Optimized Vaccines Against Congenital Infection and Maternal Reinfection with CMV
针对先天性感染和母体巨细胞病毒再感染的优化疫苗
基本信息
- 批准号:9269473
- 负责人:
- 金额:$ 32.29万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-08-06 至 2020-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdjuvantAdjuvant StudyAdultAnimal ModelAnimalsAntibodiesAntibody ResponseAntigensAreaAuditory Evoked PotentialsBiologicalBiological AssayBloodCMV glycoprotein BCaviaCellsChild health careChileClinicalClinical TrialsCollaborationsComplexContractsCytomegalovirusCytomegalovirus InfectionsCytomegalovirus VaccinesDataDefectDevelopmentDiseaseDoseEmbryoEndothelial CellsEpithelial CellsEpitope MappingEpitopesEvaluationEventFemale of child bearing ageFetusFutureGenerationsGenomeGlycoproteinsGoalsGuinea pig cytomegalovirusHarvestHealthHost DefenseHumanImmuneImmune responseImmunityImmunizationImmunizeImmunocompetentInfantInfectionInjuryKnowledgeLabyrinthitisLengthLeukocytesMF59MediatingModelingModified Vaccinia Virus AnkaraMolecular ConformationMonitorNeonatalNewborn InfantOutcomePlacentaPre-Clinical ModelPregnancyPregnant WomenProteinsRecombinantsRiskSensorineural Hearing LossSpottingsSubunit VaccinesTestingUnited StatesVaccinationVaccinesViralViral Load resultVirusWomanbasecomparativecomparative efficacycongenital cytomegaloviruscongenital infectioncytokinedisabilityefficacy studyenzyme linked immunospot assayexperimental studyfetalhead-to-head comparisonhearing impairmentimprovedinjuredinterestmortalityotoacoustic emissionplacental infectionpre-clinicalprenatalpreventprotein Bprotein complexpublic health prioritiespublic health relevancepuprecombinant virusresponseseropositivestemtransmission processvaccination strategyvaccine efficacyvaccine trialvectorvector-based vaccineyoung woman
项目摘要
DESCRIPTION (provided by applicant): Immunity to human cytomegalovirus (HCMV) following infection is complex, and not fully protective against reactivation and reinfection with new strains. Although generally asymptomatic in immunocompetent adults, infection or reinfection in pregnant women can be devastating to the developing fetus if transplacental transmission occurs. Because of the lifelong disabilities caused by congenital CMV infection, such as sensorineural hearing loss (SNHL), understanding the host defense determinants that protect the developing fetus is critical, toward the goal of developing an effective preconception vaccine. Clinical trials of an adjuvanted glycoprotein B (gB) vaccine showed protection in young women of childbearing age, but waning immunity and modest efficacy (~50%) necessitate consideration of other subunit strategies. Recent evidence suggests that the pentameric complex (PC) of CMV proteins (gH/gL/UL128/UL130/UL131) may be a more compelling vaccine target for induction of protective antibody responses than gB. This stems from the observations that antibodies to the PC potently block virus entry into epithelial and endothelial cells and leukocytes. Moreover, acquisition of these antibodies correlates with a reduced risk of fetal transmission in women with primary CMV infection. To address whether a PC-based vaccine provides superior protection against congenital CMV transmission to that conferred by a gB-based vaccine, we will compare MVA- vectored gB and PC vaccines in the guinea pig model of congenital CMV infection, using the guinea pig CMV (GPCMV) homologs of these proteins. In addition to comparing the endpoints of maternal and pup mortality, congenital GPCMV infection, and magnitude of viral load following high-dose GPCMV challenge during pregnancy (aim 1), we will compare these vaccines for their ability to confer protection against SNHL (aim 2) following low-dose challenge during pregnancy. This study will represent the first animal model evaluation of a prenatal vaccine to prevent congenital CMV-induced labyrinthitis and SNHL. We will also address a second area of significant complexity in CMV vaccines, namely, addressing the phenomena of re-infection during pregnancy. It has become increasingly clear that, in spite of preconception immunity, women can become re-infected with new strains of HCMV, and these strains can be transmitted to the fetus, leading to injury. Therefore, in aim 3, we will utilze a newly discovered strain of GPCMV, the CIDMTR strain, to model re- infection studies in the guinea pig. We will test whether MVA-PC vaccination can provide superior protection compared to gB vaccine against re-infection and subsequent fetal transmission in dams with preconception immunity to a heterotypic strain, the ATCC (22122) strain. Since most congenital CMV infections occur in the context of non-primary maternal infections, these studies will substantially advance the field, and clarify what is required of a CMV vaccine in women of childbearing age.
描述(由申请人提供):感染后对人类巨细胞病毒(HCMV)的免疫是复杂的,不能完全预防新毒株的重新激活和再次感染。虽然在具有免疫能力的成年人中一般没有症状,但如果发生经胎盘传播,孕妇的感染或再感染可能对发育中的胎儿造成毁灭性的影响。由于先天性CMV感染会导致终生残疾,如感音神经性听力损失(SNHL),了解保护发育中胎儿的宿主防御决定因素对于开发有效的早孕疫苗的目标至关重要。一种佐剂糖蛋白B(GB)疫苗的临床试验显示,在育龄的年轻女性中有保护作用,但免疫力减弱和适度的疗效(~50%)需要考虑其他亚单位策略。最近的证据表明,CMV蛋白的五聚体(PC)(Gh/gl/UL128/UL130/UL131)可能是比GB更有吸引力的保护性抗体反应的疫苗靶点。这源于观察到,针对PC的抗体有效地阻止病毒进入上皮细胞、内皮细胞和白细胞。此外,在患有CMV原发感染的妇女中,获得这些抗体与降低胎儿传播风险相关。为了说明基于PC的疫苗是否对先天性CMV传播提供了比基于GB的疫苗更好的保护,我们将在先天性CMV感染的豚鼠模型中比较MVA载体的GB和PC疫苗,使用这些蛋白的豚鼠CMV(GPCMV)同源物。除了比较母婴死亡率、先天GPCMV感染和孕期大剂量GPCMV攻击后病毒载量(目标1)的终点外,我们还将比较这些疫苗在孕期低剂量攻击后对SNHL(AIM 2)的保护能力。这项研究将是对预防先天性CMV诱导的迷路炎和SNHL的产前疫苗的第一次动物模型评估。我们还将解决CMV疫苗中第二个非常复杂的领域,即解决怀孕期间再次感染的现象。越来越清楚的是,尽管有先入为主的免疫力,女性可能会再次感染新的HCMV毒株,这些毒株可能会传播给胎儿,导致伤害。因此,在目标3中,我们将利用一种新发现的GPCMV毒株,CIDMTR毒株,来模拟豚鼠的再感染研究。我们将测试MVA-PC疫苗是否可以提供比GB疫苗更好的保护,防止对异型毒株ATCC(22122)株有预先免疫的母体再次感染和随后的胎儿传播。由于大多数先天性巨细胞病毒感染发生在非原发母体感染的背景下,这些研究将极大地推进这一领域,并澄清育龄妇女接种巨细胞病毒疫苗的必要性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mark R. Schleiss其他文献
Beyond hearing loss: exploring neurological and neurodevelopmental sequelae in asymptomatic congenital cytomegalovirus infection
超越听力损失:探索无症状先天性巨细胞病毒感染的神经和神经发育后遗症
- DOI:
10.1038/s41390-025-04232-5 - 发表时间:
2025-07-08 - 期刊:
- 影响因子:3.100
- 作者:
Meghan R. Swanson;Lauren D. Haisley;William B. Dobyns;Mark R. Schleiss - 通讯作者:
Mark R. Schleiss
Cytomegalovirus reactivation and acute and chronic complications in children with cerebral malaria: a prospective cohort study
- DOI:
10.1186/s12936-025-05293-x - 发表时间:
2025-02-17 - 期刊:
- 影响因子:3.000
- 作者:
Jonathan A. Mayhew;Andrew J. Witten;Caitlin A. Bond;Robert O. Opoka;Paul Bangirana;Andrea L. Conroy;Nelmary Hernandez-Alvarado;Mark R. Schleiss;Chandy C. John - 通讯作者:
Chandy C. John
Taking a step beyond serology: progress in the search for a biomarker predicting the risk of maternal-fetal transmission of cytomegalovirus (CMV)
超越血清学的一步:寻找预测巨细胞病毒(CMV)母婴传播风险的生物标志物的进展
- DOI:
10.1016/j.ebiom.2024.105039 - 发表时间:
2024-03-01 - 期刊:
- 影响因子:10.800
- 作者:
Mark R. Schleiss - 通讯作者:
Mark R. Schleiss
Mark R. Schleiss的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mark R. Schleiss', 18)}}的其他基金
ELISPOT Peptide Mapping Assay to Identify Novel Candidate CMV Vaccine Antigens
ELISPOT 肽图分析法鉴定新型候选 CMV 疫苗抗原
- 批准号:
9016570 - 财政年份:2015
- 资助金额:
$ 32.29万 - 项目类别:
Optimized Vaccines Against Congenital Infection and Maternal Reinfection with CMV
针对先天性感染和母体巨细胞病毒再感染的优化疫苗
- 批准号:
9120271 - 财政年份:2015
- 资助金额:
$ 32.29万 - 项目类别:
Optimized Vaccines Against Congenital Infection and Maternal Reinfection with CMV
针对先天性感染和母体巨细胞病毒再感染的优化疫苗
- 批准号:
8974656 - 财政年份:2015
- 资助金额:
$ 32.29万 - 项目类别:
ELISPOT Peptide Mapping Assay to Identify Novel Candidate CMV Vaccine Antigens
ELISPOT 肽图分析法鉴定新型候选 CMV 疫苗抗原
- 批准号:
8804125 - 财政年份:2015
- 资助金额:
$ 32.29万 - 项目类别:
Bedside-to-Bench Research Training for Pediatric Infectious Diseases Fellows
为儿科传染病研究员提供从床边到实验室的研究培训
- 批准号:
8075963 - 财政年份:2011
- 资助金额:
$ 32.29万 - 项目类别:
Bedside-to-Bench Research Training for Pediatric Infectious Diseases Fellows
为儿科传染病研究员提供从床边到实验室的研究培训
- 批准号:
8262139 - 财政年份:2011
- 资助金额:
$ 32.29万 - 项目类别:
Bedside-to-Bench Research Training for Pediatric Infectious Diseases Fellows
为儿科传染病研究员提供从床边到实验室的研究培训
- 批准号:
8495784 - 财政年份:2011
- 资助金额:
$ 32.29万 - 项目类别:
Bedside-to-Bench Research Training for Pediatric Infectious Diseases Fellows
为儿科传染病研究员提供从床边到实验室的研究培训
- 批准号:
8657402 - 财政年份:2011
- 资助金额:
$ 32.29万 - 项目类别:
Novel Strategy for Animal Model Testing of HCMV Vaccines
HCMV 疫苗动物模型测试新策略
- 批准号:
7229927 - 财政年份:2006
- 资助金额:
$ 32.29万 - 项目类别:
Transgenic Plant-Derived CMV Glycoprotein B Vaccine
转基因植物源 CMV 糖蛋白 B 疫苗
- 批准号:
7105874 - 财政年份:2006
- 资助金额:
$ 32.29万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 32.29万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 32.29万 - 项目类别:
Studentship
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 32.29万 - 项目类别:
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 32.29万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 32.29万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 32.29万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 32.29万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 32.29万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 32.29万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 32.29万 - 项目类别: